Indegene Limited has informed the Exchange about Presentation
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indegene filed a revised analyst presentation for its ongoing analyst meet (May 27-29, 2026), correcting a duplicate page from the earlier submission dated May 27, 2026. The company stated no material change in information disclosed. The presentation showcases Indegene as an AI-embedded operating partner for life sciences companies, serving 20 of the Top 20 global pharma firms. Key FY26 metrics include revenue of INR 35.1 billion with 19.4% adjusted EBITDA margin, 29.4% revenue CAGR over FY21-FY26, and a strong OCF-to-PAT ratio of 162%. The company highlighted its zero-debt balance sheet, 91 active clients, and >100% net revenue retention every year. Management indicated the FY27 pipeline is 17% higher than the prior year, with strategic ambitions to grow from ~$400M to $500M+ near-term. The company positions itself to capture market share from traditional agencies and CROs as pharma shifts to AI-driven centralized operations.
This procedural revision filing carries no immediate direct impact on the stock. However, the detailed analyst presentation provides investors with updated financial performance, strategic targets, and market positioning that could influence sentiment and valuations positively, given strong margin metrics and growth trajectory.